We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 12, 2008
Last Update Posted: May 4, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
VA Office of Research and Development
Results First Submitted: February 13, 2015  
Study Type: Observational
Study Design: Observational Model: Case Control;   Time Perspective: Prospective
Condition: HIV Infections

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment took place from September 2005 to September 2010. The population consisted of young (40 years or less) and old (50 years or more) Human Immunodeficiency Virus infected and non-infected veterans within the Greater Los Angeles VA Healthcare System with additional recruitment from the Los Angeles community in order to meet project goals.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Recruited subjects who meet any of the following criteria were excluded prior to group assignment: Brain infection other than HIV; Brain neoplasm; neurosyphilis; traumatic brain injury with L.O.C>30 mins; current diagnosis of seizure disorder; current psychotic spectrum disorders; history of drug or alcohol abuse or dependence within the past year.

Reporting Groups
Group 1 HIV-positive adults 50 and older
Group 2 HIV-positive adults 18-40 years old
Group 3 HIV-negative controls 50 and older
Group 4 HIV-negative controls 18-40 years old

Participant Flow:   Overall Study
    Group 1   Group 2   Group 3   Group 4
STARTED   106   30   50   37 
Year 2   105   28   34   20 
Year 3   100   25   29   11 
COMPLETED   100   25   29   11 
NOT COMPLETED   6   5   21   26 
Lost to Follow-up                6                5                21                26 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Group 1 HIV-positive adults 50 and older
Group 2 HIV-positive adults 18-40 years old
Group 3 HIV-negative controls 50 and older
Group 4 HIV-negative controls 18-40 years old
Total Total of all reporting groups

Baseline Measures
   Group 1   Group 2   Group 3   Group 4   Total 
Overall Participants Analyzed 
[Units: Participants]
 106   30   50   37   223 
Age, Customized 
[Units: Participants]
Between 18 and 40 years old   0   30   0   37   67 
50 years and older   106   0   50   0   156 
[Units: Participants]
Female   18   6   32   17   73 
Male   88   24   18   20   150 
Race (NIH/OMB) 
[Units: Participants]
American Indian or Alaska Native   2   0   2   0   4 
Asian   1   1   1   3   6 
Native Hawaiian or Other Pacific Islander   0   0   0   0   0 
Black or African American   59   12   36   16   123 
White   43   15   9   12   79 
More than one race   1   2   2   6   11 
Unknown or Not Reported   0   0   0   0   0 
Region of Enrollment 
[Units: Participants]
United States   106   30   50   37   223 

  Outcome Measures

1.  Primary:   Neuropsychological Status (i.e., Cognitive Functioning)   [ Time Frame: Baseline (Year 1) and 1-year follow-up (Year 2) ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Large number of subjects who were lost to follow up (i.e moved from community, did not answer follow up calls to schedule visits) resulted in a reduced sample size of subjects who completed the study.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Charles Hinkin
Organization: West Los Angeles Veterans Association
phone: 310-478-3711 ext 44214
e-mail: chinkin@ucla.edu

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00675766     History of Changes
Other Study ID Numbers: AGCG-012-04F
First Submitted: May 7, 2008
First Posted: May 12, 2008
Results First Submitted: February 13, 2015
Results First Posted: May 4, 2015
Last Update Posted: May 4, 2015